search
Back to results

Comparative Efficacy and Tolerability of No7 in Osteoarthritis of the Knee

Primary Purpose

Osteoarthritis, Knee

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Solgar No7 Complex
placebo
Sponsored by
Ambrosia - SupHerb Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Osteoarthritis, Knee

Eligibility Criteria

45 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Osteoarthritis (at least 2-nd grade according to Kellgren Classification)
  • Ability to walk independently
  • Pain Intensity of 4 or more according to Visual Analogue Scale
  • NSAIDs usage of 5 times or more per month during 3 months before the intervention
  • Ability to understand the benefits and risks of the proposed treatment and can provide answers to the required questions and fill out a questionnaire in Hebrew
  • Early consent of participants not to start a new treatment for Osteoarthritis including medication, surgery, physiotherapy, laser therapy, etc. during the period of the study (3 months) - except for a clear medical need (should report to the investigators immediately)

Exclusion Criteria:

  • Inflammatory Arthropathy, Severe Rheumatoid Arthritis, Psoriatic Arthritis or Gout
  • History of injection of pharmacological material (steroids, anesthetic, hyaluronic acid or any other pharmacological substance) into the knee joint during the six months prior to the start of the study
  • Taking of biological drugs that may affect inflammatory conditions (such as anti-TNF- alpha, etc.) or oral PO steroids - even if given to another disease, for more than 5 days during 3 months prior to the start of the study
  • Chronic administration of any anti-inflammatory drug during the study period and / or at least one month prior to commencement of the study.
  • Chronic administration of medical cannabis
  • Use of analgetics in a formulation that provides a half-life of over 24 hours (eg, Butrans, Fentanyl)
  • Chronic use of vitamin K antagonists, Heparin, Enoxaparin
  • Injury to the knee during six months prior to the experiment
  • Expectations of surgical intervention, physiotherapy or other treatment of osteoarthritis before the end of the study period
  • Significant irregularities in renal or liver function, active malignant disease in the last 3 years, heart failure, uncontrolled hypertension, active peptic ulcer, hematologic diseases, severe neurological diseases, and mental illness with seizures in the last two years.
  • Peripheral neuropathy that treated by any drug
  • High alcohol consumption (over 2 standard doses per day)
  • Sensitivity to one of the ingredients and / or sensitivity to NSAIDs. It is Possible to include a patient who is sensitive to a specific drug from the family of NSAIDs, but can take other drugs from this family.
  • Any medical condition or treatment which, in the opinion of the investigators, may mask the results of the study and / or interfere with the research questions and / or terminate the research properly and / or endanger the participant in any way during the course of the study.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Solgar No7

    Placebo for Solgar No7

    Arm Description

    Aflapin 100 mg and Collagen UC2 40 mg by mouth every 24 hours for 90 days

    Placebo 1 Capsule by mouth, every 24 hours for 90 days

    Outcomes

    Primary Outcome Measures

    Pain Intensity
    Self reported pain intensity in the scale 1-10

    Secondary Outcome Measures

    Knee Stiffness
    The stiffness of the knee according to the doctor evaluation
    Non Steroidal Anti Inflammatory Drugs Usage
    Self reported Non Steroidal Anti Inflammatory Drugs Usage
    Adverse Reactions
    Self reported Adverse Reactions

    Full Information

    First Posted
    January 9, 2018
    Last Updated
    February 20, 2018
    Sponsor
    Ambrosia - SupHerb Ltd.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03442153
    Brief Title
    Comparative Efficacy and Tolerability of No7 in Osteoarthritis of the Knee
    Official Title
    Comparative Efficacy and Tolerability of No7 in Osteoarthritis of the Knee: A Double Blind, Randomized, Placebo Controlled Clinical Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2018
    Overall Recruitment Status
    Unknown status
    Study Start Date
    March 2018 (Anticipated)
    Primary Completion Date
    May 2018 (Anticipated)
    Study Completion Date
    May 2018 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Ambrosia - SupHerb Ltd.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This study evaluates the effect of dietary supplement Solgar No7 in 76 adult Osteoarthritis of the Knee Patients, while the other half will receive placebo.
    Detailed Description
    Solgar No7 is a Dietary Supplement marketed in Israel on a regular basis with the approval of the Israeli Ministry of Health. The product is based on Herbal Extracts and Vitamins. The individual components of the product were effective in some studies in relieving pain and inflammation in such patients. This Study evaluates the effect of these components as a complex.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Osteoarthritis, Knee

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    The product in not drug or medical device (but a dietary supplement). There are 76 participants divided inti 2 groups : experimental group (38) and Placebo group (38). The period of the intervention: 90 days
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    76 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Solgar No7
    Arm Type
    Experimental
    Arm Description
    Aflapin 100 mg and Collagen UC2 40 mg by mouth every 24 hours for 90 days
    Arm Title
    Placebo for Solgar No7
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo 1 Capsule by mouth, every 24 hours for 90 days
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Solgar No7 Complex
    Intervention Description
    Solgar No7 Capsules
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    placebo
    Other Intervention Name(s)
    Placebo for Solgar No7
    Intervention Description
    Placebo tablets Cellulose
    Primary Outcome Measure Information:
    Title
    Pain Intensity
    Description
    Self reported pain intensity in the scale 1-10
    Time Frame
    Pain intensity Reported to the Doctor after one month of the treatment. Each item is scored 0-10 (0=no pain; 10=pain as bad as can be), yielding a total between 0 and 30.
    Secondary Outcome Measure Information:
    Title
    Knee Stiffness
    Description
    The stiffness of the knee according to the doctor evaluation
    Time Frame
    nee Stiffness checked by the Doctor after one month of treatment. Each item is scored 0-10 (0=no pain; 10=pain as bad as can be), yielding a total between 0 and 30
    Title
    Non Steroidal Anti Inflammatory Drugs Usage
    Description
    Self reported Non Steroidal Anti Inflammatory Drugs Usage
    Time Frame
    Pain Medication Usage as Reported to the Doctor after one month of treatment. Each item is scored as a number of the dose units that were used during the all period (0=no medications, 1=only one dose of medication etc)
    Title
    Adverse Reactions
    Description
    Self reported Adverse Reactions
    Time Frame
    Adverse Reactions as Reported to the Doctor over the period of the treatment. Each item is scored as a number of the dose units that were used during the all period (0=no adverse reactions, 1=only one adverse reaction etc)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    45 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Osteoarthritis (at least 2-nd grade according to Kellgren Classification) Ability to walk independently Pain Intensity of 4 or more according to Visual Analogue Scale NSAIDs usage of 5 times or more per month during 3 months before the intervention Ability to understand the benefits and risks of the proposed treatment and can provide answers to the required questions and fill out a questionnaire in Hebrew Early consent of participants not to start a new treatment for Osteoarthritis including medication, surgery, physiotherapy, laser therapy, etc. during the period of the study (3 months) - except for a clear medical need (should report to the investigators immediately) Exclusion Criteria: Inflammatory Arthropathy, Severe Rheumatoid Arthritis, Psoriatic Arthritis or Gout History of injection of pharmacological material (steroids, anesthetic, hyaluronic acid or any other pharmacological substance) into the knee joint during the six months prior to the start of the study Taking of biological drugs that may affect inflammatory conditions (such as anti-TNF- alpha, etc.) or oral PO steroids - even if given to another disease, for more than 5 days during 3 months prior to the start of the study Chronic administration of any anti-inflammatory drug during the study period and / or at least one month prior to commencement of the study. Chronic administration of medical cannabis Use of analgetics in a formulation that provides a half-life of over 24 hours (eg, Butrans, Fentanyl) Chronic use of vitamin K antagonists, Heparin, Enoxaparin Injury to the knee during six months prior to the experiment Expectations of surgical intervention, physiotherapy or other treatment of osteoarthritis before the end of the study period Significant irregularities in renal or liver function, active malignant disease in the last 3 years, heart failure, uncontrolled hypertension, active peptic ulcer, hematologic diseases, severe neurological diseases, and mental illness with seizures in the last two years. Peripheral neuropathy that treated by any drug High alcohol consumption (over 2 standard doses per day) Sensitivity to one of the ingredients and / or sensitivity to NSAIDs. It is Possible to include a patient who is sensitive to a specific drug from the family of NSAIDs, but can take other drugs from this family. Any medical condition or treatment which, in the opinion of the investigators, may mask the results of the study and / or interfere with the research questions and / or terminate the research properly and / or endanger the participant in any way during the course of the study.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Evgeny Vaysberg, Pharmacist
    Phone
    +972506670597
    Email
    evgenyiw@solgar.co.il
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Guy Rubin
    Organizational Affiliation
    HaEmek Medical Center, Israel
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Comparative Efficacy and Tolerability of No7 in Osteoarthritis of the Knee

    We'll reach out to this number within 24 hrs